Stroke is the leading cause of disability and one of the leading causes of death worldwide. More than 80% of all stroke syndromes are ischemic infarcts and their prevalence and cost will undoubtedly rise as the aging population increases. Despite extensive risk factor stratification and enhanced brain imaging, the etiology of stroke is still unknown in a significant proportion of patients. However, most likely atherosclerosis is the culprit in most strokes, which is a low-grade inflammatory condition with detectable biomarkers.
Platelets play an essential role in the pathogenesis of atherothrombotic cardio- and cerebrovascular events, justifying the use of antiplatelet agents in their prevention. Despite their efficacy, patients on these medications continue to suffer complications, which raises the possibility of so-called „antiplatelet resistance” that has been used to refer to the inability of these drugs to protect individuals from thrombotic events. The clinical significance of antiplatelet resistance is contradictory, due to the lack of standard methodology and randomized trials involving cerebrovascular patients. Interestingly, recent studies have shown the association of antiplatelet resistance and unfavorable outcomes such as poor recovery, early deterioration, and recurrent strokes.
Since the coagulation system plays an important role in stroke pathogenesis, blood biomarkers of coagulation and inflammation might render the possibility to differentiate which patients are at risk of poor clinical outcome. The ability to predict clinical outcome after ischemic stroke may help to improve the selection of the most appropriate therapy. Hemostatic changes during acute stroke in relation to antiplatelet resistance may predict the severity of ischemic stroke based on recent studies.
In this Research Topic, Original Research, Meta-Analysis, and Review Articles in all topics associated with platelet function, coagulation, and biomarkers of antiplatelet resistance in acute stroke care are welcome, from preclinical research to multidisciplinary clinical management.
Potential themes relevant to this collection may include but are not limited to the following listed below:
1. Antiplatelet therapy in cerebrovascular diseases.
2. The clinical significance of antiplatelet resistance in acute ischemic stroke.
3. The role of biomarkers of antiplatelet resistance in acute ischemic stroke.
4. Issues with measurement of antiplatelet resistance.
6. Platelet function in hyperacute stroke management including systemic thrombolysis and endovascular interventions.
7. Platelet function, blood coagulation, and outcome in stroke of unknown time of onset.
8. Hemostatic changes and antiplatelet resistance in early post-stroke seizures.
Stroke is the leading cause of disability and one of the leading causes of death worldwide. More than 80% of all stroke syndromes are ischemic infarcts and their prevalence and cost will undoubtedly rise as the aging population increases. Despite extensive risk factor stratification and enhanced brain imaging, the etiology of stroke is still unknown in a significant proportion of patients. However, most likely atherosclerosis is the culprit in most strokes, which is a low-grade inflammatory condition with detectable biomarkers.
Platelets play an essential role in the pathogenesis of atherothrombotic cardio- and cerebrovascular events, justifying the use of antiplatelet agents in their prevention. Despite their efficacy, patients on these medications continue to suffer complications, which raises the possibility of so-called „antiplatelet resistance” that has been used to refer to the inability of these drugs to protect individuals from thrombotic events. The clinical significance of antiplatelet resistance is contradictory, due to the lack of standard methodology and randomized trials involving cerebrovascular patients. Interestingly, recent studies have shown the association of antiplatelet resistance and unfavorable outcomes such as poor recovery, early deterioration, and recurrent strokes.
Since the coagulation system plays an important role in stroke pathogenesis, blood biomarkers of coagulation and inflammation might render the possibility to differentiate which patients are at risk of poor clinical outcome. The ability to predict clinical outcome after ischemic stroke may help to improve the selection of the most appropriate therapy. Hemostatic changes during acute stroke in relation to antiplatelet resistance may predict the severity of ischemic stroke based on recent studies.
In this Research Topic, Original Research, Meta-Analysis, and Review Articles in all topics associated with platelet function, coagulation, and biomarkers of antiplatelet resistance in acute stroke care are welcome, from preclinical research to multidisciplinary clinical management.
Potential themes relevant to this collection may include but are not limited to the following listed below:
1. Antiplatelet therapy in cerebrovascular diseases.
2. The clinical significance of antiplatelet resistance in acute ischemic stroke.
3. The role of biomarkers of antiplatelet resistance in acute ischemic stroke.
4. Issues with measurement of antiplatelet resistance.
6. Platelet function in hyperacute stroke management including systemic thrombolysis and endovascular interventions.
7. Platelet function, blood coagulation, and outcome in stroke of unknown time of onset.
8. Hemostatic changes and antiplatelet resistance in early post-stroke seizures.
